More tools:Markets·Screener·Research·Chat

LeonaBio, Inc. Common Stock (LONA) Financial Statements

LeonaBio, Inc. Common Stock
SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
FIGI BBG00C77LXM0
XNAS · usd
7.41▼ 0.61 (-7.61%)
As of 2026-09-09
Valuation
Market Cap
Enterprise Value
Trailing P/E—
Price / Sales—
EV / Revenue—
EV / EBITDA
Financial Highlights
Revenue (TTM)—
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin—
Net Debt
Trading Information
Previous Close8.02
Day's Range7.43 – 8.27
52-Week Range4.20 – 13.40
Volume251.8K
Avg Volume50.7K
Share Statistics
Shares Outstanding
Employees19
ExchangeXNAS
Listed2020-09-18
Share count as of August 4, 2026
Loading Income Statement…
Key questions about LeonaBio, Inc. Common Stock (LONA)
What is LeonaBio, Inc. Common Stock's Market Cap?
LeonaBio, Inc. Common Stock's Market Cap is $69.8M, based on as-reported figures from SEC (XBRL) filings.
What is LeonaBio, Inc. Common Stock's Enterprise Value?
LeonaBio, Inc. Common Stock's Enterprise Value is $18.7M, based on as-reported figures from SEC (XBRL) filings.
What is LeonaBio, Inc. Common Stock's EV / EBITDA?
LeonaBio, Inc. Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is LeonaBio, Inc. Common Stock's Net Income (TTM)?
LeonaBio, Inc. Common Stock's Net Income (TTM) is -$141.5M, based on as-reported figures from SEC (XBRL) filings.
What is LeonaBio, Inc. Common Stock's EBITDA?
LeonaBio, Inc. Common Stock's EBITDA is -$121.2M, based on as-reported figures from SEC (XBRL) filings.
What is LeonaBio, Inc. Common Stock's Diluted EPS (TTM)?
LeonaBio, Inc. Common Stock's Diluted EPS (TTM) is -15.01, based on as-reported figures from SEC (XBRL) filings.
What is LeonaBio, Inc. Common Stock's Net Debt?
LeonaBio, Inc. Common Stock's Net Debt is -$51.1M, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Operating expenses:
Research and development—
Milestone liability change in fair value———
General and administrative—
Legal expense————
Total operating expenses—
Loss from operations—
Other income, net—
Sermonix pre-funded warrant change in fair value———
Net loss
Comprehensive loss attributable to common stockholders—
Net loss per share attributable to common stockholders, basic—
Net loss per share attributable to common stockholders, diluted—